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Hypoxia inducible factor 1 (HIF-1) represses the transcription of pro-apoptotic bid in colorectal cancer cells in vitro. To assess the
clinical relevance of this observation, HIF-1a and Bid were assessed in serial sections of 39 human colorectal adenocarcinomas by
immunohistochemistry. In high HIF-1a nuclear-positive cell subpopulations, there was a significant reduction in Bid expression
(ANOVA, P¼0.04). Given the role of Bid in drug-induced apoptosis, these data add impetus to strategies targeting HIF-1 for
therapeutic gain.
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Approximately 30–50% of patients diagnosed with colorectal
cancer (CRC) (35000 new cases per year in the United Kingdom)
will either present with or develop distant metastases. For these
patients, management with combination chemotherapy offers
survival prolongation (Saunders and Iveson, 2006), but the disease
course is frequently characterised by acquired drug resistance
manifesting as tumour progression and the need to alter treatment.
Tumour hypoxia and suppression of apoptosis are important
drivers of drug (Makin and Dive, 2003; Shannon et al, 2003) and
radiotherapy (Saunders et al, 2002) resistance in solid tumours.
The transcription factor, hypoxia inducible factor-1 (HIF-1),
consists of a and b subunits: the former is ubiquitinated and
degraded in normoxia but stabilised in hypoxia; the latter is
constitutively expressed independent of oxygen (Semenza, 2003).
Under hypoxic conditions, HIF-1a is translocated to the cell
nucleus where it dimerises with HIF-1b to bind hypoxia-
responsive elements (HRE) in target gene promoters. Hypoxia
inducible factor-1 targets encode multiple components of adaptive
pathways, including increased glucose uptake, pH stabilisation (via
carbonic anhydrase (CA-IX) (Wykoff et al, 2000), and regulation of
apoptosis (Greijer and van der Wall, 2004).
Of the Bcl-2 family of apoptosis regulatory proteins, pro-
apoptotic Bid is of particular interest as it links the mitochondrial
(intrinsic)- and death receptor (extrinsic)-driven apoptotic
pathways (Andersen et al, 2005; Letai, 2008). In exploring links
between tumour hypoxia and apoptosis, we previously demon-
strated that HIF-1 repressed transcription of bid in CRC cell lines
in vitro (Erler et al, 2004). Moreover, a reciprocal relationship was
demonstrated between hypoxic regions and Bid expression in CRC
xenografted tumours (Erler et al, 2004). This study sought to
determine the clinical significance of these observations and
examined the relationship between the number of cells with
stabilised nuclear HIF-1a and Bid expression in ex vivo CRC tissue.
To assess HIF-1 functionality, nuclear HIF-1a expression was
examined in parallel with CA-IX.
MATERIALS AND METHODS
Patients
Tissues from 39 patients with colorectal adenocarcinoma were
used from the joint Christie Hospital and Hope Hospital CRC
tissue banks (Manchester, UK) under ethical approvals (LREC-02/
051; 03/SM/449). Clinical details have been published previously
(Renehan et al, 2000; Bibi et al, 2006). All samples were from
luminal tumour edges and processed, formalin-fixed, and paraffin-
embedded using standard operational procedures.
Immunohistochemical staining and analysis
Antibodies used were mouse monoclonal anti-human HIF-1a
(610958, diluted 1:100, BD Biosciences, Oxford, UK); goat
polyclonal anti-human Bid (1:50, Santa Cruz Biotechnology, CA,
USA); and mouse anti-human CA-IX (anti-MN 75, 1:20, kindly
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Figure 1 Experimental controls for immunohistochemistry. (A) Substitution of the primary antibody with mouse IgG1 at the same dilution was used as a
negative control in all experiments. (B) Normal large bowel mucosa was an additional IgG1-negative control. (C) Representative immunostaining for HIF-1a
demonstrating immunopositivity in close proximity to blood vessels (arrows). Both nuclear and cytoplasmic staining is seen. (D and E) Formalin-fixed and
paraffin-embedded pellets of HT-29 human colorectal cancer cells previously cultured for 16h in normoxic or hypoxic conditions (1% O2) and stained for
HIF-1a. Only nuclear staining, as seen in hypoxic cells, was considered positive; we considered the diffuse cytoplasmic staining in normoxic cells as
nonspecific, reasoning that HIF-1 is not transcriptionally active in cytosol. (F and G) Formalin-fixed and paraffin-embedded pellets of Bid knockout and wild-
type mouse embryonic fibroblasts (kindly provided by SJ Korsmeyer, Harvard Medical School, Boston, MA, USA) were used as positive and negative controls
for Bid. Pellets were processed identical to that for human tumour specimens. (H–J) Bid immunostaining in human adenocarcinomas with representative
sections of weak (score 1), moderate (score 2), and strong (score 3) staining. The magnification bar for all sections is 50mm.
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sprovided by Bayer Diagnostics). Sections of 4 mm were stained as
previously described (Wilson et al, 2000). Before HIF-1a, and Bid
immunostaining, antigen retrieval was by microwaving in 10mM
citrate buffer (pH 6: 2 10min), and the Tyramide Signal
Amplication System (NEN Life Sciences, Boston, MA, USA) was
used to optimise HIF-1a staining. All staining was completed using
diaminobenzidene (EnVision HRP kit, Dako, Cambridge, USA) for
2–3min before counterstaining with haematoxylin. A variety of
approaches were used to control the experiment (see legend,
Figure 1). Batch-to-batch variation was assessed using two regions
with clear high or low nuclear HIF-1a expression, comparing
sections from these with each batch.
Hypoxia inducible factor-1a expression was heterogeneous
both within and between tumours. To quantify this, a scoring
system was developed with nuclear HIF-1a expression as a
continuous variable, and the number of immunopositive cells
expressed per area (see below). Immunopositivity was defined by
strong nuclear staining; cytoplasmic staining alone was considered
negative. The mean HIF-1a score was based on the average of three
counts. A pilot study identified that all tumours were HIF-1a
immunopositive, but that high- and low-positive subpopulations
existed using a cutoff of 20 positive cells per 40000mm
2
(200 200).
Expression scores for Bid and CAIX were semiquantitative based
on stain intensity (Rhodes et al, 2000). Bid was assigned as weak,
moderate, or strong (scored as 1, 2, or 3, respectively). For CA-IX,
some tumours exhibited no staining and, therefore, the scores
included zero. From these scores, a consensus of three observers
was taken.
To quantify specifically the relationship between nuclear HIF-1a
and Bid expression, a technique of paired same area serial analysis
was developed. Each specimen was sectioned to produce serial
slides 4mm apart. Slides were viewed and imaged using a Nikon
E600 microscope ( 100 magnification). A 200 200mm
2 boxed
area of high HIF-1a staining was selected and an identical box
placed on the corresponding area on the Bid slide. This procedure
was repeated for low HIF-1a areas resulting in 78 paired analyses.
A series of experiments were repeated for paired HIF-1a and
CA-IX.
Assessment of internal validity
Interobserver variations were assessed to confirm the validity of
our analytic approaches. The number of nuclear HIF-1a-immuno-
positive cells within each boxed area was counted independently
by three observers (MMS, MPS, and CD). For Bid and CA-IX,
tumour images were randomised before the same observer
assessed staining within the assigned boxes.
Statistical analysis
Distributions of mean nuclear HIF-1a were skewed, and were
therefore log-transformed. Comparisons of means used univariate
and multivariate analysis of variance (ANOVA). Other immuno-
staining scores were treated as ordinal. Interobserver variation of
continuous data (mean nuclear HIF-1a) was assessed using
intraclass correlations: for ordinal data (Bid and CA-IX),
k-correlations were performed. All analyses were performed using
STATA (version 9.0, College Station, TX, USA).
RESULTS
Immunopositivity for nuclear HIF-1a was present in all adeno-
carcinomas but was heterogeneous within tumours. Hypoxia
inducible factor-1a staining was noted adjacent to areas of
necrosis but also adjacent to blood vessels (Figure 1C). Bid
immunostaining was diffuse non-nuclear and positive in all
sections but its intensity varied between tumours (Figure 1E).
Areas of high HIF-1a immunopositivity were often associated
with low Bid expression, whereas areas of low HIF-1a immuno-
positivity were associated with variable Bid expression. This was
quantified as follows: for high-HIF-1a areas, there was a stepwise
reduction in Bid expression with increasing mean HIF-1a
positivity (ANOVA, P¼0.04) (Figure 2A). This relationship was
absent for low HIF-1a areas.
Mean HIF-1a immunopositivity correlated with the total
















  20   11  8 
1    2    3 
High HIF-1 -positive 
cell subpopulations












  11   16  12 
1   2     3
Bid
ANOVA, P = 0.04
ANOVA, P = 0.86





0    1   2   3
5   13 11   10  
Ca-IX
Ca-IX staining score 
Figure 2 (A) Hypoxia inducible factor-1a-positive nuclei scores vs Bid
category scores in the paired same area serial analysis. Upper panel
represents high mean HIF-1a scores (greater than 20 positive nuclei per
area). Lower panel represents low mean HIF-1a scores. Boxes represent
200 200mm
2. Geometric means (horizontal lines) are compared across
the categories using an ANOVA model. Y axis is log-transformed.
n indicates number of tumours per Bid category score. (B) Similar graphic
representation of HIF-1a-positive nuclei scores vs CA-IX expression.
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scell density. To assess this further, a multivariate ANOVA model
was generated, and demonstrated the attenuation of the extent of
inverse association between mean HIF-1a and Bid expression in
the high HIF-1a subpopulations (P¼0.07).
In the assessment of HIF-1 functionality, there was coincident
staining of mean HIF-1a immunopositivity with CA-IX immuno-
positivity (ANOVA, P¼0.06) (Figure 2B).
Internal validity
The intraclass correlation for HIF-1a immunopositivity counts
(among high HIF-1a areas) was 0.77 (95 confidence interval: 0.67–
0.88), with an estimated reliability of 91%. The k-correlations for
observer 1 vs 2, 1 vs 3, and 2 vs 3 were as follows: Bid: 0.72, 0.72,
and 0.83; CA-IX: 0.55, 0.75, and 0.56; respectively.
DISCUSSION
We purposefully limited our clinical study design to test a single
hypothesis that HIF-1 represses bid transcription leading to
reduced Bid expression in ex vivo CRC having shown that
hypoxia-driven downregulation of Bid occurred via a HIF-1-
dependent pathway in CRC cell lines in vitro. We had demon-
strated in vitro that this mechanism was operational during
hypoxic resistance to etoposide and oxaliplatin, which was
overcome to a degree by forced maintained expression of Bid.
When CRC lines were xenografted into CD1 nude mice, a striking
reciprocal relationship was observed between the hypoxia marker
pimonidazole, which formed a penumbra adjacent to necrotic
regions in tumours (a location typically associated with chronic
hypoxia), and Bid expression, which stained more positively away
from the necrotic regions (Erler et al, 2004). However, although the
tumour–xenograft model is widely used for preclinical testing of
anticancer agents, it has two key limitations – first, the degree of
genetic heterogeneity observed in most human tumours does not
exist in xenografts; and second, the native stromal microenviron-
ment is lacking. Thus, it was necessary to test the HIF-1a and Bid
relationship in human tissues.
The human data that emerged were consistent with HIF-1a-
mediated repression of Bid occurring in human CRC. However,
this relationship was modest, and attenuated after the adjustment
for cell density. It is not surprising that HIF-1a expression varied
after this adjustment, as its induction may be influenced by
hypoxic and non-hypoxic mechanisms (Semenza, 2003). Hence,
for example, in the human specimens, HIF-1a immunostaining was
observed adjacent to oxygen-rich intratumoral blood vessels. One
may expect the relationship between transcriptionally active HIF-1
and Bid to be independent of these mechanisms, but other
regulators of Bid expression (e.g., p53 loss) (Sax et al, 2002) may
also be operational in CRC tissue. We speculate that the absence of
a relationship in low-score HIF-1a may indicate a threshold level
for bid transcriptional repression to predominate.
As an additional dimension of complexity, it is increasingly clear
that modulation of tumour apoptosis may occur through HIF-1-
independent pathways, for example, Bad activation and cell
survival through an adenosine–Akt pathway in glioblastoma cells
(Merighi et al, 2007).
Strengths of our study were as follows: first, we used robust
staining controls; second, we determined HIF-1a immunopositiv-
ity as a continuous variable allowing analyses that included
adjustments for cell density; third, we developed and validated the
use of the paired same area serial analysis; and fourth, we assessed
HIF-1a functionality in the CRC tissues by demonstrating
coincident expression with CA-IX, an established HIF-1 transcrip-
tional target.
Tumour hypoxia offers a selective approach to the treatment of
cancer, as, with only few exceptions, normal tissues do not usually
experience low oxygen tension. Accordingly, HIF-1 is considered
an attractive anticancer drug target (Semenza, 2003; Welsh and
Powis, 2003; Melillo, 2007). Hypoxia inducible factor-1 inhibition
could potentially ablate several adaptive responses that allow
tumour cell survival under conditions of compromised oxidative
phosphorylation. Negating HIF-1 functions improves response to
therapy (Hussein et al, 2006) and small-molecule HIF-1 inhibitors
are currently in early clinical trial (Semenza, 2003; Melillo, 2007).
The data presented here give additional impetus to targeting HIF-1
for therapeutic gain, as it is predicted to increase Bid levels and, in
turn, reduce the threshold for apoptosis.
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